Startseite Kongressberichte 2020 ESMO VIRTUAL 2020 Breast cancer Proffered Paper - Breast cancer, early stage

Proffered Paper - Breast cancer, early stage

LINK to Proffered Paper - Breast cancer, early stage

LINK to STREAM (needs an ESMO registration)

LBA11 - IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)

The abstract concludes: In pts with eTNBC, A + neoadj chemo significantly improved pCR rates regardless of PD-L1 status with an acceptable safety profile.

See also @ Online First from The Lancet:

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Read also ESMO's Daily Reporter News:

Increased Clarity on the Role of Immunotherapy in Early TNBC


159O - Prognostic value of tumour infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study group

The abstract concludes: In young (<40 year), systemically untreated, N0, TNBC patients TIL provide important prognostic information. Subsequent investigations to de-escalate systemic therapy in a subgroup of young TNBC patients may be warranted.


160O - Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC)

The abstract concludes: While there was no difference in survival following NACT with iddEPC or PM(Cb) for the entire cohort, the subgroup of HR+/HER2- BC significantly benefits from treatment with iddEPC. This supports the concept of effective therapy beyond pCR in luminal BC pts.


LBA12 - PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer

The abstract concludes: Within the PALLAS trial, at IA2, two years of adjuvant palbociclib with ET did not improve iDFS compared to ET alone. Ongoing long-term follow-up and additional clinical and translational analyses will explore the effect of P in this patient population.


161O - Randomized preoperative window of opportunity (WOO) study with the CDK4/6 inhibitor abemaciclib in early breast cancer (EBC) patients and differential gene expression pathway analyses with palbociclib

The abstract concludes: Short-term pre-operative abemaciclib was associated to significant antiproliferative effect as well as a change in cell cycle biomarkers like pRb, Cyclin D1 and Cyclin E2 by IHC and by GE array. Pooled GE pathway analyses with palbociclib treated patients showed significant effect on cell cycle pathways although no significant differences were seen between the two CDK4/6 inhibitors. Further analyses with the pooled GE arrays will be presented.